Kyprolis

Kyprolis

carfilzomib

Manufacturer:

Amgen

Distributor:

Zuellig
/
Agencia Lei Va Hong
Concise Prescribing Info
Contents
Carfilzomib
Indications/Uses
In combination w/ lenalidomide & dexamethasone or dexamethasone alone for the treatment of adult patients w/ multiple myeloma who have received at least 1 prior therapy.
Dosage/Direction for Use
In combination w/ lenalidomide & dexamethasone Administer as a 10-min IV infusion, on 2 consecutive days, each wk for 3 wk (days 1, 2, 8, 9, 15 & 16), followed by a 12-day rest period (days 17-28). Starting dose: 20 mg/m2 (max dose 44 mg) in cycle 1 on days 1 & 2. If tolerated, dose should be increased to 27 mg/m2 (max dose 60 mg) on day 8 of cycle 1. From cycle 13, omit days 8 & 9. In combination w/ dexamethasone Administer as a 30-min IV infusion on 2 consecutive days, each wk for 3 wk (days 1, 2, 8, 9, 15 & 16) followed by a 12-day rest period (days 17-28). Starting dose: 20 mg/m2 (max dose 44 mg) in cycle 1 on days 1 & 2. If tolerated, dose should be increased to 56 mg/m2 (max dose 123 mg) on day 8 of cycle 1.
Contraindications
Special Precautions
Risk of new or worsening cardiac failure, myocardial ischaemia & MI; QT interval prolongation; acute resp distress syndrome, acute resp failure & acute diffuse infiltrative pulmonary disease eg, pneumonitis & interstitial lung disease; pulmonary HTN; dyspnoea; HTN; acute renal failure; tumour lysis syndrome; infusion reactions; haemorrhage & thrombocytopenia; venous thromboembolic events; hepatic failure; thrombotic microangiopathy; posterior reversible encephalopathy syndrome. Monitor patients for evidence of vol overload. Control HTN prior to starting treatment. Routinely evaluate for HTN while on Kyprolis & treat as needed. Monitor renal function at least mthly. Ensure adequate hydration before cycle 1. Monitor platelet counts frequently during treatment. Monitor liver enzymes & bilirubin at treatment initiation & mthly during treatment. Female patients of child bearing potential & male patients must use effective contraception. May decrease the efficacy of OCs. Patients on a controlled Na diet. Minor influence on the ability to drive & use machines. Pregnancy. Childn. Elderly ≥75 yr.
Adverse Reactions
Anaemia, fatigue, thrombocytopenia, nausea, diarrhoea, pyrexia, dyspnoea, resp tract infection, cough, neutropenia.
Drug Interactions
Caution should be observed when co-administered w/ substrates of CYP1A2, 2C8, 2C9, 2C19 & 2B6 eg, OCs; & substrates of P-gp (eg, digoxin, colchicine).
ATC Classification
L01XX45 - carfilzomib ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Kyprolis inj 30 mg
Packing/Price
1's
Form
Kyprolis inj 60 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in